Pharmaceuticals, Biotechnology and Life Sciences
Lineage has applied for grant funding from the California Institute for Regenerative Medicine (CIRM) to support the use of VAC, Lineage’s allogeneic dendritic cell therapy, toward the development of a potential vaccine against SARS-CoV-2, the virus which causes COVID-19.
announced the pricing of the sale of 1,672,689 shares of common stock of OncoCyte Corporation at a price to buyers of $2.27 per share, representing the closing price of OncoCyte common stock on April 23, 2020.
Lineage Cell Therapeutic has presented results of testing OpRegen, which continues to be well tolerated with increased visual acuity observed…
Lineage Cell Therapeutic’s comparative clinical trial met its primary endpoint of change in hemifacial volume at six months (p<.001), which…